Theranostic porphyrin dyad nanoparticles for magnetic resonance imaging guided photodynamic therapy

Biomaterials

Volumn 35, Issue 24, 2014, Pages 6379-6388

  Liang, Xiaolong ^a   Li, Xiaoda ^b   Jing, Lijia ^b   Yue, Xiuli ^b   Dai, Zhifei ^a  

^a PEKING UNIVERSITY   (China)

^b HARBIN INSTITUTE OF TECHNOLOGY   (China)

Author keywords

Magnetic resonance imaging; Nanoparticles; Photodynamic therapy; Porphyrin; Theranostic

Indexed keywords

LOADING; MAGNETIC RESONANCE IMAGING; MANGANESE; METAL NANOPARTICLES; NANOPARTICLES; PHOTODYNAMIC THERAPY; PHOTOSENSITIZERS; TUMORS;

COVALENT ATTACHMENT; HEALTHY TISSUES; INTRAVENOUS INJECTIONS; METAL-FREE PORPHYRIN; MRI CONTRAST AGENTS; PHOTODYNAMIC THERAPY (PDT); SYSTEMIC CIRCULATION; THERANOSTIC;

PORPHYRINS;

MANGANESE; NANOPARTICLE; PORPHYRIN;

ANIMAL; ANTIBODY SPECIFICITY; CELL SURVIVAL; CHEMISTRY; DIAGNOSTIC USE; HELA CELL LINE; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUDE MOUSE; PHOTOCHEMOTHERAPY; TUMOR VOLUME; ULTRASTRUCTURE; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; CELL SURVIVAL; HELA CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MAGNETIC RESONANCE IMAGING; MANGANESE; MICE, NUDE; NANOPARTICLES; ORGAN SPECIFICITY; PHOTOCHEMOTHERAPY; PORPHYRINS; TUMOR BURDEN;

EID: 84901386705     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.04.094     Document Type: Article

References (57)

1. Sharman W.M., Allen C.M., Van Lier J.E. Photodynamic therapeutics: basic principles and clinical applications. Drug Discov Today 1999, 4:507-517.
2. Dolmans D.E., Fukumura D., Jain R.K. Photodynamic therapy for cancer. Nat Rev Cancer 2003, 3:380-387.
3. Celli J.P., Spring B.Q., Rizvi I., Evans C.L., Samkoe K.S., Verma S., et al. Imaging and photodynamic therapy: mechanisms, monitoring, and optimization. Chem Rev 2010, 110:2795-2838.
4. Agostinis P., Berg K., Cengel K.A., Foster T.H., Girotti A.W., Gollnick S.O., et al. Photodynamic therapy of cancer: an update. CA Cancer J Clin 2011, 61:250-281.
5. Dougherty T.J., Gomer C.J., Henderson B.W., Jori G., Kessel D., Korbelik M., et al. Photodynamic therapy. JNatl Cancer Inst 1998, 90:889-905.
6. Teng I.-T., Chang Y.-J., Wang L.-S., Lu H.-Y., Wu L.-C., Yang C.-M., et al. Phospholipid-functionalized mesoporous silica nanocarriers for selective photodynamic therapy of cancer. Biomaterials 2013, 34:7462-7470.
7. Foote C.S. Mechanisms of photosensitized oxidation. Science 1968, 162:963-970.
8. van Dongen G.A., Visser G.W., Vrouenraets M.B. Photosensitizer-antibody conjugates for detection and therapy of cancer. Adv Drug Deliv Rev 2004, 56:31-52.
9. Chen B., Pogue B.W., Hasan T. Liposomal delivery of photosensitising agents. Expert Opin Drug Deliv 2005, 2:477-487.
10. Derycke A.S., de Witte P.A. Liposomes for photodynamic therapy. Adv Drug Deliv Rev 2004, 56:17-30.
11. Roy I., Ohulchanskyy T.Y., Pudavar H.E., Bergey E.J., Oseroff A.R., Morgan J., et al. Ceramic-based nanoparticles entrapping water-insoluble photosensitizing anticancer drugs: a novel drug-carrier system for photodynamic therapy. JAm Chem Soc 2003, 125:7860-7865.
12. Ohulchanskyy T.Y., Roy I., Goswami L.N., Chen Y., Bergey E.J., Pandey R.K., et al. Organically modified silica nanoparticles with covalently incorporated photosensitizer for photodynamic therapy of cancer. Nano Lett 2007, 7:2835-2842.
13. Ethirajan M., Chen Y., Joshi P., Pandey R.K. The role of porphyrin chemistry in tumor imaging and photodynamic therapy. Chem Soc Rev 2011, 40:340-362.
14. Huang P., Lin J., Wang S., Zhou Z., Li Z., Wang Z., et al. Photosensitizer-conjugated silica-coated gold nanoclusters for fluorescence imaging-guided photodynamic therapy. Biomaterials 2013, 34:4643-4654.
15. Wang C., Cheng L., Liu Y., Wang X., Ma X., Deng Z., et al. Imaging-guided pH-sensitive photodynamic therapy using charge reversible upconversion nanoparticles under near-infrared light. Adv Funct Mater 2013, 23:3077-3086.
16. Rong P., Yang K., Srivastan A., Kiesewetter D.O., Yue X., Wang F., et al. Photosensitizer loaded nano-graphene for multimodality imaging guided tumor photodynamic therapy. Theranostics 2014, 4:229-239.
17. Gross S., Gilead A., Scherz A., Neeman M., Salomon Y. Monitoring photodynamic therapy of solid tumors online by BOLD-contrast MRI. Nat Med 2003, 9:1327-1331.
18. Jäger H.R., Taylor M.N., Theodossy T., Hopper C. MR imaging-guided interstitial photodynamic laser therapy for advanced head and neck tumors. AJNR Am J Neuroradiol 2005, 26:1193-1200.
19. Li G., Slansky A., Dobhal M.P., Goswami L.N., Graham A., Chen Y., et al. Chlorophyll-a analogues conjugated with aminobenzyl-DTPA as potential bifunctional agents for magnetic resonance imaging and photodynamic therapy. Bioconjug Chem 2005, 16:32-42.
20. Eljamel M.S., Goodman C., Moseley H. ALA and photofrin fluorescence-guided resection and repetitive PDT in glioblastoma multiforme: a single centre phase III randomised controlled trial. Lasers Med Sci 2008, 23:361-367.
21. Zilidis G., Aziz F., Telara S., Eljamel M.S. Fluorescence image-guided surgery and repetitive photodynamic therapy in brain metastatic malignant melanoma. Photodiagnosis Photodyn Ther 2008, 5:264-266.
22. Spernyak J.A., White W.H., Ethirajan M., Patel N.J., Goswami L., Chen Y., et al. Hexylether derivative of pyropheophorbide-a (HPPH) on conjugating with 3gadolinium(III) aminobenzyldiethylenetriaminepentaacetic acid shows potential for invivo tumor imaging (MR, Fluorescence) and photodynamic therapy. Bioconjug Chem 2010, 21:828-835.
23. Huang P., Li Z., Lin J., Yang D., Gao G., Xu C., et al. Photosensitizer-conjugated magnetic nanoparticles for invivo simultaneous magnetofl{ligature}uorescent imaging and targeting therapy. Biomaterials 2011, 32:3447-3458.
24. Tanimoto A., Nakashima J., Kohno H., Shinmoto H., Kuribayashi S. Prostate cancer screening: the clinical value of diffusion-weighted imaging and dynamic MR imaging in combination with T2-weighted imaging. JMagn Reson Imaging 2007, 25:146-152.
25. Ward J. New MR techniques for the detection of liver metastases. Cancer Imaging 2006, 6:33-42.
26. Chan K.W., Wong W.-T. Small molecular gadolinium(III) complexes as MRI contrast agents for diagnostic imaging. Coord Chem Rev 2007, 17:2428-2451.
27. Sakuma H. Magnetic resonance imaging for ischemic heart disease. JMagn Reson Imaging 2007, 26:3-13.
28. Major J.L., Meade T.J. Bioresponsive, cell-penetrating, and multimeric MR contrast agents. Acc Chem Res 2009, 42:893-903.
29. Sieber M.A., Steger-Hartmann T., Lengsfeld P., Pietsch H. Gadolinium-based contrast agents and NSF: evidence from animal experience. JMagn Reson Imaging 2009, 30:1268-1276.
30. Prince M.R., Zhang H.L., Prowda J.C., Grossman M.E., Silvers D.N. Nephrogenic systemic fibrosis and its impact on abdominal imaging. Radiographics 2009, 29:1565-1574.
31. Idée J.M., Port M., Dencausse A., Lancelot E., Corot C. Involvement of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: an update. Radiol Clin North Am 2009, 47:855-869.
32. Tromsdorf U.I., Bruns O.T., Salmen S.C., Beisiegel U., Weller H. Ahighly effective, nontoxic T1 MR contrast agent based on ultrasmall PEGylated iron oxide nanoparticles. Nano Lett 2009, 9:4434-4440.
33. Kessinger C.W., Togao O., Khemtong C., Huang G., Takahashi M., Gao J. Investigation of invivo targeting kinetics of αvβ3-specific superparamagnetic nanoprobes by high temporal resolution-MRI. Theranostics 2011, 1:263-275.
34. Kim T., Momin E., Choi J., Yuan K., Zaidi H., Kim J., et al. Mesoporous silica-coated hollow manganese oxide nanoparticles as positive T1 contrast agents for labeling and MRI tracking of adipose-derived mesenchymal stem cells. JAm Chem Soc 2011, 133:2955-2961.
35. Wang S., Westmoreland T. Correlation of relaxivity with coordination number in six-, seven-, and eight-coordinate Mn(II) complexes of pendant-arm cyclen derivatives. Inorg Chem 2009, 48:719-727.
36. Zhang Z., He R., Yan K., Guo Q., Lu Y., Wang X., et al. Synthesis and invitro and invivo evaluation of manganese(III) porphyrin-dextran as a novel MRI contrast agent. Bioorg Med Chem Lett 2009, 19:6675-6678.
37. Lee T., Zhang X., Dhar S., Faas H., Lippard S.J., Jasanoff A. Invivo imaging with a cell-permeable porphyrin-based MRI contrast agent. Chem Biol 2010, 17:665-673.
38. Zhang X.A., Lovejoy K.S., Jasanoff A., Lippard S.J. Water-soluble porphyrins as a dual-function molecular imaging platform for MRI and fluorescence zinc sensing. Proc Natl Acad Sci U S A 2007, 104:10780-10785.
39. Pan D., Caruthers S.D., Senpan A., Schmieder A.H., Wickline S.A., Lanza G.M. Revisiting an old friend: manganese-based MRI contrast agents. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2011, 3:162-173.
40. Chen C.W., Cohen J.S., Myers C.E., Sohn M. Paramagnetic metalloporphyrins as potential contrast agents in NMR imaging. FEBS Lett 1984, 168:70-74.
41. Koenig S.H., Brown R.D., Spiller M. The anomalous relaxivity of Mn3+(TPPS4). Magn Reson Med 1987, 4:252-260.
42. Fiel R.J., Button T.M., Gilani S., Mark E.H., Musser D.A., Henkelman R.M., et al. Proton relaxation enhancement by manganese(III)TPPS4 in a model tumor system. Magn Reson Imaging 1987, 5:149-156.
43. Lyon R.C., Faustino P.J., Cohen J.S., Katz A., Mornex F., Colcher D., et al. Tissue distribution and stability of metalloporphyrin MRI contrast agents. Magn Reson Med 1987, 4:24-33.
44. Zong Y., Wang X., Goodrich K.C., Mohs A.M., Parker D.L., Lu Z.R. Contrast-enhanced MRI with new biodegradable macromolecular Gd(III) complexes in tumor-bearing mice. Magn Reson Med 2005, 53:835-842.
45. Liang X., Li X., Yue X., Dai Z. Conjugation of porphyrin to nanohybrid cerasomes for photodynamic diagnosis and therapy of cancer. Angew Chem Int Ed Engl 2011, 50:11622-11627.
46. Jing L., Liang X., Li X., Yang Y., Dai Z. Covalent attachment of Mn-porphyrin onto doxorubicin-loaded poly(lactic acid) nanoparticles for potential magnetic resonance imaging and pH-sensitive drug delivery. Acta Biomater 2013, 9:9434-9441.
47. Jin T., Yoshioka Y., Fujii F., Komai Y., Seki J., Seiyama A. Gd3+-functionalized near-infrared quantum dots for invivo dual modal (fluorescence/magnetic resonance) imaging. Chem Commun 2008, 5764-5766.
48. LeCours S.M., DiMagno S.G., Therien M.J. Exceptional electronic modulation of porphyrins through meso-arylethynyl groups. electronic spectroscopy, electronic structure, and electrochemistry of [5,15-Bis[(aryl)ethynyl]-10,20-diphenylporphinato]zinc(II) Complexes. X-ray crystal structures of [5,15-Bis[(4'-fluorophenyl)ethynyl]- 10,20-diphenylporphinato]zinc(II) and 5,15-Bis[(4'-methoxyphenyl)ethynyl]-10,20-diphenylporphyrin. JAm Chem Soc 1996, 118:11854-11864.
49. LeCours S.M., Guan H.W., DiMagno S.G., Wang C.H., Therien M.J.J. Push-pull arylethynyl porphyrins: new chromophores that exhibit large molecular first-order hyperpolarizabilities. JAm Chem Soc 1996, 118:1497-1503.
50. LeCours S.M., Philips C.M., Paula J.C.D., Therien M.J. Synthesis, transient absorption, and transient resonance raman spectroscopy of novel electron donor-acceptor complexes: [5,15-Bis[(4'-nitrophenyl)ethynyl]-10,20- diphenylporphinato]copper(II) and [5-[[4'-(Dimethylamino)phenyl]ethynyl]-15-[(4″-nitrophenyl)ethynyl]-10,20-diphenylporphinato]copper(II). JAm Chem Soc 1997, 119:12578-12589.
51. McCarthy J.R., Weissleder R. Model systems for fluorescence and singlet oxygen quenching by metalloporphyrins. ChemMedChem 2007, 2:360-365.
52. Yang H., Zhuang Y., Hu H., Du X., Zhang C., Shi X., et al. Silica-coated manganese oxide nanoparticles as a platform for targeted magnetic resonance and fluorescence imaging of cancer cells. Adv Funct Mater 2010, 20:1733-1741.
53. Caravan P. Strategies for increasing the sensitivity of gadolinium based MRI contrast agents. Chem Soc Rev 2006, 35:512-523.
54. Song Y., Kohlmeir E.K., Meade T.J. Synthesis of multimeric MR contrast agents for cellular imaging. JAm Chem Soc 2008, 130:6662-6663.
55. Zhang S., Merritt M., Woessner D.E., Lenkinski R.E., Sherry A.D. PARACEST agents: modulating MRI contrast via water proton exchange. Acc Chem Res 2003, 36:783-790.
56. Taylor K.M.L., Kim J.S., Rieter W.J., An H., Lin W.L., Lin W.B. Mesoporous silica nanospheres as highly efficient MRI contrast agents. JAm Chem Soc 2008, 130:2154-2155.
57. Pan D., Caruthers S.D., Hu G., Senpan A., Scott M.J., Gaffney P.J., et al. Ligand-directed nanobialys as theranostic agent for drug delivery and manganese-based magnetic resonance imaging of vascular targets. JAm Chem Soc 2008, 130:9186-9187.